Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE-CD: obefazimod in moderately to severely active Crohn's disease
2023-508234-34-00Phase 2Authorised
- Sponsor
- Abivax
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of obefazimod in Crohn's disease (4 arms), sponsored by Abivax. Primary endpoints: Change from baseline in CDAI score at Week 12 and Change from baseline in CDAI score at Week 52. Planned start Jan 2025; status: authorised.
02
Drugs
obefazimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-508234-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508234-34-00.